Get the Stockscreener App
2.95
4.84%
-0.15
After Hours:
3.00
0.05
+1.69%
Nucana Plc Adr stock is traded at $2.95, with a volume of 71,804.
It is down -4.84% in the last 24 hours and down -10.88% over the past month.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
See More
Previous Close:
$3.10
Open:
$3.13
24h Volume:
71,804
Relative Volume:
0.95
Market Cap:
$12.28M
Revenue:
-
Net Income/Loss:
$-33.44M
P/E Ratio:
-0.1841
EPS:
-16.0242
Net Cash Flow:
$-28.30M
1W Performance:
-8.10%
1M Performance:
-10.88%
6M Performance:
-75.25%
1Y Performance:
-98.69%
1-Day Range:
$2.89
$3.13
1-Week Range:
$2.89
$3.35
52-Week Range:
$2.78
$268.00
Nucana Plc Adr Stock (NCNA) Company Profile
Compare NCNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NCNA
Nucana Plc Adr
|
2.95 | 12.90M | 0 | -33.44M | -28.30M | -16.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-03-22 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-22-20 | Initiated | Truist | Buy |
| Jul-24-20 | Initiated | Oppenheimer | Outperform |
| Aug-19-19 | Initiated | H.C. Wainwright | Buy |
| Oct-19-18 | Initiated | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | Citigroup | Buy |
| Oct-23-17 | Initiated | Jefferies | Buy |
| Oct-23-17 | Initiated | William Blair | Outperform |
View All
Nucana Plc Adr Stock (NCNA) Latest News
NuCana is falling today: what traders are watching (January 9) - Traders Union
NuCana stock price forecast: Sellers remain in control as NCNA edges toward support - Traders Union
NuCana stock drops 2.16% as sellers dominate below key moving averages - Traders Union
NuCana stock price forecast: rangebound days expected as NCNA holds steady near resistance - Traders Union
NuCana Appoints Theresa Bruce as Chief Operating Officer - GlobeNewswire Inc.
NuCana (NASDAQ:NCNA) Trading Up 1.6% – Here’s Why - Defense World
NuCana plc ADR (NCNA) Stock Price History & Data - Traders Union
NuCana plc ADR (NCNA) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
NuCana reports partial responses in melanoma treatment trial - Investing.com
NuCana stock rises after securing key patent in China for cancer drug - Investing.com
Taking the lead: NuCana plc ADR (NCNA) - Setenews
NuCana compliant with all Nasdaq continued listing criteria - MSN
Rising Momentum in European ADRs: A Strategic Entry Point for US Investors - AInvest
NuCana regains Nasdaq compliance, extends cash runway into 2029 - Investing.com
What recovery options are there for NuCana plc Depositary ReceiptJuly 2025 Update & Expert Curated Trade Ideas - Newser
How institutional ownership impacts NuCana plc Depositary Receipt stockWeekly Trade Recap & Accurate Trade Setup Notifications - Newser
Wall Street Today: Dow, Nasdaq, S&P 500 open flat as investors focus on China tariff deadline; Nvidia down 1.3% - Mint
NuCana plc ADR’s Shares Reel: -92.65% Quarterly Revenue Decline Amid 14.58M Market Cap - investchronicle.com
HEPS’s Stock Dilemma: D-MARKET Electronic Services & Trading ADR’s Market Performance and Outlook - investchronicle.com
NuCana plc Announces Change in American Depository Shares Ratio to Enhance Liquidity and Nasdaq Compliance - Quiver Quantitative
GIBO Holdings Ltd (NASDAQ: GIBO): Down -99.40% In 2025, Outlook Remains Negative - stocksregister.com
NuCana Stock Set to Reverse Split on Friday, August 8th (NASDAQ:NCNA) - Defense World
NuCana Cancels Series A Warrants Post-ATM Execution - The Globe and Mail
NuCana completes cancellation of all remaining Series A Warrants - Investing.com
NuCana Announces ADS Ratio Change to Enhance Liquidity - The Globe and Mail
NuCana to implement 1:200 reverse ADS split to boost share price - Investing.com
Nucana Plc shares surge 45% in premarket after receiving Nasdaq delisting notice and strong industry performance. - AInvest
NuCana (NCNA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
NCNA Gets Second Nasdaq Notice; Hearing to Delay Potential Delisting - Stock Titan
NuCana enters $100 million at-the-market sales agreement for ADS offering - Investing.com
NuCana CEO takes leave of absence due to health reasons - Investing.com
nucana plc announces annual report release and upcoming agm - Investing.com
NuCana's Melanoma Breakthrough: Key Drug Advances to Expansion Trial, Q1 Losses Drop 63% Year-over-Year - Stock Titan
NuCana prices $7 million direct offering of ADSs and warrants - Investing.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Zacks Investment Research
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Yahoo Finance
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNANuCana plc ADR Earnings - Finviz
NuCana stock downgraded by William Blair after halted cancer study - Investing.com
Nucana Plc Share Price (NCNA.US) - London South East
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana (NCNA) Stock Trends and Sentiment 2026 - MarketBeat
NuCana (NCNA) Stock Forecast and Price Target 2026 - MarketBeat
NuCana regains Nasdaq compliance with bid price rule - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
NuCana plcADR (NCNA) Price Target Increased by 15.39% to 5.10 - Nasdaq
NuCana plc (NCNA) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
NuCana plc Sponsored ADR Earnings and Revenue – NASDAQ:NCNA - TradingView — Track All Markets
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks - Yahoo Finance
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq
Nucana Plc Adr Stock (NCNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):